Multiple Myeloma Program

Multiple myeloma is a cancer of the bone marrow. It results from abnormal growth of plasma cells. Plasma cells produce antibodies, but as malignant plasma cells multiply they produce large quantities of abnormal antibodies, which then collect in the blood and urine. The growth of the plasma cell tumor eventually destroys the bone around it and leads to bone pain, kidney damage, and a weakened immune system.
Although currently not curable, multiple myeloma is a treatable cancer. In recent years, the life expectancy and quality of life for those with this cancer has steadily improved, and a number of new treatment options have transformed multiple myeloma into a disease than can be managed on a long-term basis.

Our Multidisciplinary Team

Under the leadership of Sundar Jagannath, MD, Mount Sinai’s Multiple Myeloma Program is the largest of its kind in New York City, and is utilized by myeloma patients from around the world. Our doctors are experts in the diagnosis and treatment of all stages of multiple myeloma. We offer a multidisciplinary team approach to treatment that brings together specialists who provide compassionate, comprehensive, and personalized care. This involves the Bone Marrow Transplantation service, and the Departments of Cardiology, Rheumatology, Nephrology, Pathology, and the Institute of Genomics and Multiscale Biology.

Sundar Jagannath, MD
Ajai Chari, MD
Hearn Jay Cho, MD
Samir Parekh, MD

Nurse Practitioners:
Donna Catamero, ANP-BC
Natalie Belostotsky, FNP-BC
Daniel Verina, ACNP-BC
Juliet Escalon, NP

Registered Nurse
Arlynn Brion, RN

Social Worker
Yu Mee Song, LCSW

Diagnosis and Treatment

In many patients, multiple myeloma is detected by a routine blood test when no other symptoms are present.  Symptoms of multiple myeloma may include persistent fatigue or pain or recurrent unexplained infections.

Mount Sinai’s comprehensive Multiple Myeloma Program provides the highest level of care for myeloma patients throughout the entire spectrum of the disease. Patients with early stages of the disease are closely monitored, as treatment paradigms for multiple myeloma can change every 3 – 5 years.

Treatments are tailored to each patient’s needs, and may include: chemotherapy, bone marrow transplantation, vaccine therapy, and other novel drugs and targeted therapies such as monoclonal antibodies.

Clinical trials are also a critical component of the program. Mount Sinai offers numerous clinical trials for multiple myeloma patients. For more information, see the list of currently open clinical trials in multiple myeloma. Mount Sinai also participates in multicenter research studies in conjunction with the Multiple Myeloma Research Foundation, including studies that will help researchers develop drugs targeted toward specific genes and tailor therapies according to the patient’s need.

Contact Us

Tel: 212-241-7873
Fax: 212-241-8608